Q1 2024 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2024-05-15 · accession 0001085146-24-002547
$955.5M
Reported value
23
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | NATERA INC | $182.9M | 19.1% | 2,000,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $134.7M | 14.1% | 5,660,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $121.7M | 12.7% | 2,900,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $65.8M | 6.89% | 1,526,787 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $57.1M | 5.98% | 8,500,000 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $52.6M | 5.51% | 4,239,780 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $50.9M | 5.33% | 745,000 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $41.8M | 4.37% | 100,000 | PUT | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $33.2M | 3.47% | 2,248,324 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $33.2M | 3.47% | 6,527,491 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $33.1M | 3.46% | 1,144,242 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $31.9M | 3.33% | 5,953,825 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $24.3M | 2.54% | 3,932,082 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $15.4M | 1.61% | 2,000,000 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $14.8M | 1.54% | 585,900 | PUT | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $14.2M | 1.48% | 1,625,000 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $11.3M | 1.18% | 2,001,727 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $10.7M | 1.12% | 12,022,957 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $8.4M | 0.88% | 515,190 | Common | SOLE |
| 12233L107 | BNR | BURNING ROCK BIOTECH LTD | $7.0M | 0.73% | 9,640,914 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $5.5M | 0.57% | 1,068,527 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $2.7M | 0.28% | 396,379 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $2.3M | 0.25% | 133,877 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.